Successful treatment pure red cell aplasia after ABO major mismatched allogeneic hematopoietic stem cell transplantation with avatrombopag and low dose rituximab

CONCLUSION: Low-dose rituximab and avatrombopag may be an effective treatment for patients with PRCA after major ABO-incompatible allo-HSCT. The patients should be treated at least 90 days post transplantation if conventional erythropoietin therapy fails.PMID:38351735 | DOI:10.1111/trf.17743

https://pubmed.ncbi.nlm.nih.gov/38351735/?utm_source=no_user_agent&utm_medium=rs...

Source: Transfusion - February 14, 2024 Category: Hematology Authors: Junjie Cao Shaoyan Lu Danjie Luo Renzhi Pei Ying Lu Dong Chen Xiaohong Du Shuangyue Li Source Type: research